In tumors, IFN-I can activate anti-tumor immune responses by recruiting natural killer cells and expanding CD4+ and CD8+ T cells; conversely, mild and persistent IFN-I signaling can lead to immunosuppression by inducing mediators involved in T cell exhaustion, such as PD-L1, IDO, and IL-10 (36). This evidence concerns the gene CD8A and neoplasm.